SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw unusually large options trading on Monday. Investors purchased 48,643 put options on the company. This is an increase of 19% compared to the average volume of 40,961 put options.
Wall Street Analysts Forecast Growth
SLS has been the subject of several analyst reports. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.00.
Check Out Our Latest Research Report on SELLAS Life Sciences Group
SELLAS Life Sciences Group Price Performance
SELLAS Life Sciences Group stock traded down $0.33 during midday trading on Monday, reaching $7.53. The stock had a trading volume of 3,178,609 shares, compared to its average volume of 7,843,897. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $15.88. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -37.65 and a beta of 2.73. The firm’s fifty day simple moving average is $11.03 and its two-hundred day simple moving average is $8.77.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after purchasing an additional 1,630 shares during the period. California State Teachers Retirement System grew its position in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after purchasing an additional 1,709 shares in the last quarter. Nykredit A S acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at approximately $27,000. Pictet Asset Management Holding SA increased its stake in SELLAS Life Sciences Group by 15.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 27,688 shares of the company’s stock valued at $341,000 after buying an additional 3,704 shares during the period. Finally, Private Advisor Group LLC increased its stake in SELLAS Life Sciences Group by 36.0% in the 3rd quarter. Private Advisor Group LLC now owns 21,278 shares of the company’s stock valued at $262,000 after buying an additional 5,628 shares during the period. Hedge funds and other institutional investors own 17.38% of the company’s stock.
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
